Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Starpharma Holdings Limited ( (AU:SPL) ) just unveiled an update.
Starpharma Holdings Limited announced the results of its 2025 Annual General Meeting, where all proposed resolutions were carried with significant majorities. The successful resolutions, including the re-election of a board director and approval of performance rights, reflect strong shareholder support and are expected to positively impact the company’s strategic direction and stakeholder confidence.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company specializing in dendrimer technology, which is used to improve health outcomes for patients with serious illnesses such as cancer. The company offers a portfolio of dendrimer-based products, including clinical-stage DEP® assets, preclinical radiopharmaceutical assets, research collaborations, and commercially marketed over-the-counter products.
Average Trading Volume: 1,201,214
Technical Sentiment Signal: Buy
Current Market Cap: A$186.1M
Learn more about SPL stock on TipRanks’ Stock Analysis page.